Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Takara Bio Inc
4974Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc. Address: 7-4-38 Nojihigashi, Kusatsu, Japan, 525-0058
Analytics
Precio Objetivo de WallStreet
231 502.56 JPYRelación P/E
142.8192Rentabilidad por dividendo
1.63 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 4974
Análisis de dividendos 4974
Aumento del dividendo durante 5 años
833 %Crecimiento continuo
11 añosRatio de pago medio en 5 años
21 %Tendencia del payout 4974
Valoración de la acción 4974
Finanzas 4974
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |